Mereo BioPharma Group plc
MREO
$2.30
$0.177.98%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | 1.00M | 1.00M | 10.00M | 10.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 1.00M | 1.00M | 10.00M | 10.00M |
| Cost of Revenue | -- | -273.00K | -508.00K | 2.92M | 2.58M |
| Gross Profit | -- | 1.27M | 1.51M | 7.08M | 7.43M |
| SG&A Expenses | 26.43M | 23.57M | 23.08M | 17.88M | 18.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.71M | 39.07M | 38.90M | 35.65M | 37.14M |
| Operating Income | -45.71M | -38.07M | -37.90M | -25.65M | -27.14M |
| Income Before Tax | -43.25M | -45.85M | -37.38M | -26.87M | -30.00M |
| Income Tax Expenses | -- | -532.00K | -532.00K | -532.00K | -532.00K |
| Earnings from Continuing Operations | -43.25 | -45.32 | -36.85 | -26.34 | -29.47 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.25M | -45.32M | -36.85M | -26.34M | -29.47M |
| EBIT | -45.71M | -38.07M | -37.90M | -25.65M | -27.14M |
| EBITDA | -45.13M | -37.48M | -37.31M | -25.04M | -26.57M |
| EPS Basic | -1.46 | -1.56 | -1.31 | -0.95 | -1.12 |
| Normalized Basic EPS | -0.18 | -0.20 | -0.17 | -0.12 | -0.14 |
| EPS Diluted | -1.46 | -1.56 | -1.31 | -0.95 | -1.12 |
| Normalized Diluted EPS | -0.18 | -0.20 | -0.17 | -0.12 | -0.14 |
| Average Basic Shares Outstanding | 591.45M | 576.40M | 559.37M | 542.70M | 527.43M |
| Average Diluted Shares Outstanding | 118.29M | 115.28M | 111.87M | 108.54M | 105.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |